PolyPeptide Group Reports Strong Revenue Growth for 2025

PolyPeptide Group AG concluded its financial year 2025 with significant revenue growth and improved profitability. The company announced a revenue of approximately EUR 389 million, representing a 15.6% increase compared to 2024, driven mainly by metabolic therapeutics. At constant currency rates, this figure exceeded guidance expectations.

Profitability saw a marked improvement, with the EBITDA margin rising from 7.5% in 2024 to between 11-12%. Capital expenditures aligned with projections, slightly exceeding EUR 100 million. The company also reported enhanced operating cash flow and financing flexibility, closing the year with EUR 75 million in cash and EUR 51 million undrawn credit available.

CEO Juan José Gonzalez highlighted the company's strong execution across its global network and its positioning within the growing GLP-1 market. PolyPeptide aims to double its revenue from 2023 by 2028, with an EBITDA margin target approaching 25% for that year.